Publicaciones (39) Publicaciones de MYRIAN ABURTO BARRENECHEA

2024

  1. Influence of physical activity on the prognosis of COPD patients: the HADO.2 score – health, activity, dyspnoea and obstruction

    ERJ Open Research, Vol. 10, Núm. 1

2023

  1. Change in physical activity related to admission for exacerbation in COPD patients

    Respiratory Medicine, Vol. 212

  2. Impact of COVID-19 Infection on Patients with Preexisting Interstitial Lung Disease: A Spanish Multicentre Study

    Archivos de Bronconeumologia, Vol. 59, Núm. 4, pp. 273-276

  3. Screening criteria for interstitial lung disease associated to rheumatoid arthritis: Expert proposal based on Delphi methodology

    Reumatologia Clinica, Vol. 19, Núm. 2, pp. 74-81

2022

  1. Changes in health-related quality of life as a marker in the prognosis in COPD patients

    ERJ Open Research, Vol. 8, Núm. 1

  2. Different Faces of Idiopathic Pulmonary Fibrosis With Preserved Forced Vital Capacity

    Archivos de Bronconeumologia, Vol. 58, Núm. 2, pp. 135-141

  3. SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 1: Epidemiology, risk factors and prognosis

    Reumatologia Clinica, Vol. 18, Núm. 8, pp. 443-452

  4. SER-SEPAR recommendations for the the management of rheumatoid arthritis-related interstitial lung disease. Part 2: Treatment

    Reumatologia Clinica, Vol. 18, Núm. 9, pp. 501-512

  5. Screening of interstitial lung disease in patients with rheumatoid arthritis: A systematic review

    Reumatologia Clinica, Vol. 18, Núm. 10, pp. 587-596

2021

  1. Checking Siblings of Patients with Idiopathic Pulmonary Fibrosis as a Scheme for Early Disease Detection

    Annals of the American Thoracic Society

2020

  1. Complications and hospital admission in the following 90 days after lung cryobiopsy performed in interstitial lung disease

    Respiratory Medicine, Vol. 165

  2. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

    The Lancet Respiratory Medicine, Vol. 8, Núm. 5, pp. 453-460

  3. Predictive factors over time of health-related quality of life in COPD patients

    Respiratory research, Vol. 21, Núm. 1, pp. 138

2019

  1. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study

    The Lancet Respiratory Medicine, Vol. 7, Núm. 9, pp. 771-779

  2. COPD classification models and mortality prediction capacity

    International Journal of COPD, Vol. 14, pp. 605-613

2018

  1. Diagnosis of Idiopathic Pulmonary Fibrosis: Differential Diagnosis

    Medical sciences (Basel, Switzerland), Vol. 6, Núm. 3

  2. Importance of early diagnosis and treatment in idiopathic pulmonary fibrosis

    Expert Review of Respiratory Medicine

2016

  1. Chronic obstructive pulmonary disease subtypes. transitions over time

    PLoS ONE, Vol. 11, Núm. 9

  2. Noninvasive ventilation for severely acidotic patients in respiratory intermediate care units: Precision medicine in intermediate care units

    BMC Pulmonary Medicine, Vol. 16, Núm. 1

  3. Outcomes of a telemonitoring-based program (telEPOC) in frequently hospitalized COPD patients

    International Journal of COPD, Vol. 11, Núm. 1, pp. 2919-2930